Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma

Seventy-five percent of lung adenocarcinomas with epidermal growth factor receptor (EGFR) mutations respond to treatment with the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib; however, drug-resistant tumors eventually emerge. In 60% of cases, resistant tumors carry a secondary mutation...

Full description

Saved in:
Bibliographic Details
Main Authors: Politi, Katerina, Fan, Pang-Dian, Shen, Ronglai, Zakowski, Maureen, Varmus, Harold
Format: Artigo
Language:Inglês
Published: The Company of Biologists Limited 2010
Subjects:
Research Report
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2806903/
https://ncbi.nlm.nih.gov/pubmed/20007486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1242/dmm.003681
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items